Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Outline
- Measles
- Measles infections 2019
- Measles and herd immunity
- Historic hors d’oeuvres
- Measles virus identified and the push for a vaccine!
- In the UK measles vaccines not immediately celebrated!
- MMR: a vaccine equity development
- Measles vaccine hesitancy - the reasons
- The measles virus and its stealth weaponry
- Tuberculosis
- Tuberculosis: its nature and origins (1)
- Tuberculosis: its nature and origins (2)
- Tuberculosis: one step forwards…
- …but one step back
- Attenuation of the TB bacterium
- A TB vaccine for infants arrives
- It took time for different countries to vaccinate infants
- Sadly, the vaccine found to be non-effective in adults!
- The antibiotic solution but not a slam dunk
- Tuberculosis - the end game
- Poliomyelitis
- Poliomyelitis: a lifechanging ‘picovirus’
- Not a new disease but it took time to unlock the aetiology
- The late 1800s saw major advances
- Transmission of poliomyelitis: the Swedish discovery
- The pathogen identified - ‘virus’ discovery
- A Harvard “faux” claim trumps a Swedish discovery
- Pathogenesis and vaccines
- The vaccine trial
- Vaccine trials: triumph and alarm bells
- An oral vaccine evolution
- Vaccine reversion - an attenuation risk
- Vaccine reversion - a potential solution
- Until a new OPV arrives: the mixed world of polio vaccination
- Thank you
Topics Covered
- The history of measles
- Measles and herd immunity
- The discovery of measles virus
- Vaccine development
- The reasons for measles vaccine hesitancy
- The history of tuberculosis (TB)
- TB is a dangerous widespread bacterial disease
- Vaccine developed for children
- Antibiotic solutions for adults
- The history of Poliomyelitis
- The discovery of the virus
- Pathogenesis and vaccines
- The mixed world of polio vaccination
Links
Series:
Categories:
Therapeutic Areas:
External Links
Talk Citation
Rees, A.R. (2023, May 31). The history of vaccines 2 [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 21, 2024, from https://doi.org/10.69645/DHCC2667.Export Citation (RIS)
Publication History
Financial Disclosures
- Royalties paid by Elsevier on sales of History of Vaccines book.
The history of vaccines 2
Published on May 31, 2023
60 min
Other Talks in the Series: The Immune System - Key Concepts and Questions
Transcript
Please wait while the transcript is being prepared...
0:00
Hello, my name is Anthony Rees.
I'm a chemist turned biochemist.
I was a university lecturer
in molecular biophysics
at the University
of Oxford and later
Professor and Head
of biochemistry
at the University of Bath.
My field of interest
is immunology
with a special intereste
in antibodies.
Since 2012, I've been writing
about the history of antibodies
and more recently vaccines.
The lectures in this
three-part series relate
to the history of vaccines.
In January of 2022 last year,
my book on the
history of vaccines
was published and
it's from this book
that I've selected
a few examples
with pathogens that
have afflicted
the human population
over thousands of years.
We'll look at some of
the early curative
and often crude measures used
before the advent of modern
medical technologies.
And in particular,
the seismic effect of
vaccines on preventing
human disease and
reducing mortality.
1:02
In this second lecture,
we'll be looking at the
history of vaccines
for three different diseases.
Measles and poliomyelitis
caused by viruses
and tuberculosis a
bacterial disease.
1:16
On the title, I've indicated
measles, still a serious
disease of childhood,
which might surprise you.
1:24
Measles and rubella,
sometimes or maybe more
commonly called German measles
are exanthematous diseases.
You can see that
derives from Greek.
They're characterized by
simultaneous skin eruptions
in different parts of the body.
Mumps as well joins them
as three diseases
caused by RNA viruses.
Measles, which technically
is called rubeola,
and mumps are paramyxoviruses
from that family,
but sit in different
genera that family,
while rubella is a togavirus.
Just to note,
rubeola for measles
is not commonly used
since it can be easily
confused with rubella,
so we'll call it
measles from now on.
None of the three viruses
is known to have an
animal host yet.
The need for prevention
of infection
with the measles virus is
critical for avoidance
of a highly contagious
disease that during 2019
caused more than 200,000
deaths globally.
That's data from the WHO
and the US Centers
for Disease Control,
mainly among children
under the age of five.
You can see from the slide,
if you just look at the top 2
colours in the right-hand list,
that more than a 1000
deaths or infections
per annum occur in
something like 38 percent
of the countries in the world.
It's not as if measles
has gone away.
Often the infection
leads to complications
affecting around 30 percent
of infected individuals.
Complications include diarrhoea
around one in 12 cases,
otitis media inflammation
of the middle ear,
that's one in 14,
pneumonia one in 17
and in rare cases
acute encephalitis,
around one in 1000 cases.